# NCT04512235 (NCT04512235)

> A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04512235
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Alexion Pharmaceuticals, Inc.
- Conditions: AL Amyloidosis
- Interventions: CAEL-101; Placebo; cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Enrollment: 281
- Primary outcome: A Hierarchical Combination of Time to All-cause Mortality and Frequency of Cardiovascular Hospitalizations (CVHs) Analyzed by Win Ratio
- Primary outcome: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04512235